PROKHealthcare · BiotechnologyThe 7 Wall Street analysts covering ProKidney Corp. hold a median 12-month price target of $5.75 — +201.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores ProKidney Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (62): Sales and profits are climbing, and climbing faster than before.
Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PROK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +201.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 16 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 15 July 2025 | UBS | Maintains | Buy | — |
| 14 July 2025 | Guggenheim | Maintains | Buy | — |
| 9 July 2025 | Citigroup | Maintains | Buy | — |
| 30 June 2025 | B of A Securities | Downgrade | Underperform | — |
| 30 Sept 2024 | JP Morgan | Initiates | Neutral | — |
| 10 Sept 2024 | Guggenheim | Initiates | Buy | — |
| 4 Sept 2024 | B of A Securities | Maintains | Neutral | — |
| 10 June 2024 | Jefferies | Maintains | Buy | — |
| 29 May 2024 | B of A Securities | Maintains | Neutral | — |
| 7 Mar 2024 | Morgan Stanley | Assumes | Equal-Weight | $3.00 |
| 2 Jan 2024 | B of A Securities | Downgrade | Neutral | — |
| 25 July 2023 | BTIG | Initiates | Buy | — |
| 21 Dec 2022 | Jefferies | Initiates | Buy | — |
| 10 Nov 2022 | Morgan Stanley | Initiates | Equal-Weight | — |
| 18 Oct 2022 | UBS | Initiates | Buy | — |
| 14 Oct 2022 | Citigroup | Initiates | Buy | — |
| 2 Sept 2022 | Evercore ISI Group | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PROK appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, ProKidney Corp. returned −29.5% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 1% of US stocks
Cheaper than 52% of US stocks
Cheaper than 82% of US stocks
Higher than 8% of US stocks
Higher than 15% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 19% of US stocks
Higher than 12% of US stocks
Higher than 99% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ProKidney Corp. has a market value of $762.4M and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $818K. The latest quarter shrank 32.1% year on year.
Net income over the same four quarters: −$165.8M, a −20263.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$159.7M.
Trailing P/E: −3.7×; forward P/E: −3.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 224.08%, paying out 0% of earnings.
ProKidney Corp. employs 231 people — $4K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ProKidney Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
In an article titled "20 stocks likely to lose money even if the bull market continues," Market Watch highlights stocks considered poor bets that are likely to lose ground even during bull markets. ProKidney Corp. (PROK) is listed among these stocks.
Why it matters — A PROK watcher would care because the article identifies the company as one likely to underperform even in a rising market.
ProKidney Corp., a single-asset biotech with lead therapy rilparencel, received a rating downgrade from Seeking Alpha. The report cites weak Phase 2 data with confounding factors and no robust efficacy evidence, a cash position of $181.6M with high burn, and a runway extending only into mid-2027 that raises going-concern doubts, with Phase 3 PROACT data in 2027 seen as pivotal.
Why it matters — PROK watchers would care because the item highlights concerns over the company's dwindling cash runway and the uncertain outlook for its only pipeline asset ahead of pivotal Phase 3 data.
ProKidney Corp. reported a Q2 loss of $0.15 per share, wider than the Zacks Consensus Estimate of a $0.13 loss and the $0.13 loss a year ago. The company also missed revenue estimates.
Why it matters — The quarter came in worse than analyst expectations on both earnings and revenue, signalling a weaker-than-anticipated period for the company.
The 7 Wall Street analysts covering ProKidney Corp. have a median 12-month price target of $5.75, with estimates ranging from $1 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering ProKidney Corp., 4 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ProKidney Corp. 30 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, ProKidney Corp. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (62 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +201.0% from the last close, and Ticker Nerd's factor model ranks ProKidney Corp. 30 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ProKidney Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PROK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $12 over the next 12 months.
ProKidney Corp. returned -29.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
ProKidney Corp. Class A Ordinary Shares represent equity in ProKidney, a clinical-stage biotechnology company focused on developing cell-based therapies for chronic kidney disease.
The most recent item we track (Market Watch, 27 Aug 2026): "20 stocks likely to lose money even if the bull market continues". In an article titled "20 stocks likely to lose money even if the bull market continues," Market Watch highlights stocks considered poor bets that are likely to lose ground even during bull markets. ProKidney Corp. (PROK) is listed among these stocks.
ProKidney Corp. Class A Ordinary Shares represent equity in ProKidney, a clinical-stage biotechnology company focused on developing cell-based therapies for chronic kidney disease. The company’s work centers on proprietary autologous cell therapy platforms designed to support kidney function in patients with advanced kidney disease and diabetes. Its lead therapeutic program is directed at treating moderate to severe diabetic kidney disease and other chronic kidney conditions, placing ProKidney in the broader renal therapeutics sector. The company’s current business is concentrated on research, clinical development, and the advancement of its cell therapy candidates, making it a specialized participant in the biotechnology market. ProKidney Corp. is headquartered in Winston-Salem, North Carolina, and its Class A ordinary shares are one of the company’s publicly traded equity classes.
CEO Dr. Bruce Culleton M.D. · 231 employees · United States · https://prokidney.com
